Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Nuvectis Pharma, Inc. before investing.

In this article, we go over a few key elements for understanding Nuvectis Pharma, Inc.’s stock price such as:

• Nuvectis Pharma, Inc.’s current stock price and volume
• Why Nuvectis Pharma, Inc.’s stock price changed recently
• Upgrades and downgrades for NVCT from analysts
• NVCT’s stock price momentum as measured by its relative strength

About Nuvectis Pharma, Inc. (NVCT)

Before we jump into Nuvectis Pharma, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Want to learn more about Nuvectis Pharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Nuvectis Pharma, Inc..

Nuvectis Pharma, Inc.’s Stock Price as of Market Close

As of September 18, 2026, 4:00 PM, CST, Nuvectis Pharma, Inc.’s stock price was $22.000.

Nuvectis Pharma, Inc. is up 2.9% from its previous closing price of $21.380.

During the last market session, Nuvectis Pharma, Inc.’s stock traded between $21.060 and $23.000. Currently, there are approximately 23.48 million shares outstanding for Nuvectis Pharma, Inc..

Nuvectis Pharma, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Nuvectis Pharma, Inc. Stock Price History

Nuvectis Pharma, Inc.’s (NVCT) price is currently down 3.21% so far this month.

During the month of September, Nuvectis Pharma, Inc.’s stock price has reached a high of $25.190 and a low of $20.000.

Over the last year, Nuvectis Pharma, Inc. has hit prices as high as $29.275 and as low as $5.550. Year to date, Nuvectis Pharma, Inc.’s stock is up 191.39%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Nuvectis Pharma, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 18, 2026, there were analysts who downgraded Nuvectis Pharma, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Nuvectis Pharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Nuvectis Pharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Nuvectis Pharma, Inc. (NVCT) by visiting AAII Stock Evaluator.

Relative Price Strength of Nuvectis Pharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 18, 2026, Nuvectis Pharma, Inc. has a weighted four-quarter relative price strength of 32.83%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how Nuvectis Pharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Nuvectis Pharma, Inc. Stock Price: Bottom Line

As of September 18, 2026, Nuvectis Pharma, Inc.’s stock price is $22.000, which is up 2.9% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Nuvectis Pharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.